Device Trial Radar · NCT05071963
INSPIRE Pipeline™ Shield Post Approval Study
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
246
Actual
Start
Dec 20, 2021
Primary completion
Jan 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Medtronic Neurovascular Clinical AffairsPublic (MDT)
- Sponsor type
- Industry
- First posted
- Oct 8, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ ("Pipeline™ Shield Device") in a real-world post approval setting within the United States.
Conditions
- Intracranial Aneurysm
Interventions
Treatment of Intracranial AneurysmsDevice
Embolization of aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of the composite outcome (Occlusion of the target aneurysm, Significant parent artery stenosis, Retreatment of the target aneurysm) at 1 year post-procedure.Time frame: 1 year
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Yale New Haven Hospital
New Haven, Connecticut
Baptist Medical Center Jacksonville
Jacksonville, Florida
13 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.